Miltefosine hydrate

• Catalog No.: M9198
• M. F.: C21H48NO5P
• M. W.: 425.583281
• Purity: ≥98% (HPLC)

SYNONYMS

• IUPAC name: hydrate hexadecyl 2-(trimethylazaniumyl)ethyl phosphate
• IUPAC Traditional name: hydrate miltex
• Synonyms: HePC; Hexadecyl phosphocholine; Choline hexadecyl phosphate; Impavido; Miltex

DATABASE IDS

• MDL Number: MFCD12828861

PROPERTIES

• Description: zwitterionic
• Empirical Formula (Hill Notation): C21H46NO4P · xH2O
• Purity: ≥98% (HPLC)
• Apperance: white to off-white powder
• Solubility: H2O: >2 mg/mL
• GHS Signal Word: Warning
• GHS Hazard statements: H302-H317
• European Hazard Symbols: Harmful (Xn)
• GHS Precautionary statements: P280
• RID/ADR: UN 2811 6.1/PG 3
• Risk Statements: 22-43
• Safety Statements: 36/37
• Storage Temperature: 2-8°C
• Hazard Class: 6.1
• UN Number: 2811
• Packing Group: 3
• German water hazard class: 3

DETAILS

Description (English)

Biochem/physiol Actions
Miltefosine induces apoptosis of triple-negative (TN) breast cancer cells by activation of p38 MAPK pathway and differential down regulation of Akt signaling. Miltefosine is an effective anti-tumor treatment of cutaneous lymphoma, cutaneous metastatic melanoma, squamous cell carcinoma, and cutaneous metastases of breast cancer. It also shows remarkable effectiveness against visceral leishmaniasis.1 Both the anti-tumor and the antiprotozoal activities appear to be exerted first by insertion of the molecule into the plasma membrane where it interferes with phospholipid metabolism.
Miltefosine or HePC induces death of triple-negative (TN) breast cancer cells. Miltefosine exerts various modes of action leading to different cell death processes, i.e. apoptosis or non-apoptosis, depending on TN breast cancer cell types. These processes involve the activation of p38 MAPK pathway and differential down regulation of Akt signaling. Miltefosine has been used for breast cancer skin metastases, and is an efficient topical anti-tumoral treatment in patients with cutaneous lymphoma, cutaneous metastases of melanoma and squamous cell carcinoma.

Description (简体中文)

Biochem/physiol Actions
Miltefosine induces apoptosis of triple-negative (TN) breast cancer cells by activation of p38 MAPK pathway and differential down regulation of Akt signaling. Miltefosine is an effective anti-tumor treatment of cutaneous lymphoma, cutaneous metastatic melanoma, squamous cell carcinoma, and cutaneous metastases of breast cancer. It also shows remarkable effectiveness against visceral leishmaniasis.1 Both the anti-tumor and the antiprotozoal activities appear to be exerted first by insertion of the molecule into the plasma membrane where it interferes with phospholipid metabolism.
Miltefosine or HePC induces death of triple-negative (TN) breast cancer cells. Miltefosine exerts various modes of action leading to different cell death processes, i.e. apoptosis or non-apoptosis, depending on TN breast cancer cell types. These processes involve the activation of p38 MAPK pathway and differential down regulation of Akt signaling. Miltefosine has been used for breast cancer skin metastases, and is an efficient topical anti-tumoral treatment in patients with cutaneous lymphoma, cutaneous metastases of melanoma and squamous cell carcinoma.